Clobetasol ameliorates aphthous ulceration in renal transplant patients on sirolimus

American Journal of Transplantation

Volumn 7, Issue 3, 2007, Pages 714-717

  Chuang, P ^a   Langone, A J ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aphthous ulceration; Immunosuppressive therapy; Rapamycin; Renal transplant; Side effect; Sirolimus; Skin

Indexed keywords

CLOBETASOL; CYCLOSPORIN; RAPAMYCIN; TACROLIMUS;

ABSENCE OF SIDE EFFECTS; ADULT; APHTHOUS ULCER; ARTICLE; CHEEK MUCOSA; CLINICAL ARTICLE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENCY; DRUG SUBSTITUTION; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIP; MALE; OROPHARYNX; PERIODONTIUM; PRIORITY JOURNAL; TONGUE; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; CLOBETASOL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SIROLIMUS; STOMATITIS, APHTHOUS;

EID: 33847743084     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01678.x     Document Type: Article

References (20)

1. Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: A review of the evidence. Kidney Int 2001; 59: 3-16.
2. Groth CG, Backman L, Morales JM et al. Sirolimus (Rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999; 67: 1036-1042.
3. Hong JC, Kahan BD. Sirolimus-induced thrombocytopenia and leucopenia in renal transplant recipients: Risk factors, incidence, progression, and management. Transplantation 2000; 69: 2085-2090.
4. Mendez R, Gonwa T, Yang HC, Weinstein S, Jensik S, Steinberg S. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 1 year. Transplantation 2005; 80: 303-309.
5. Morelon E, Stern M, Kreis H. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 2000; 343: 225-226.
6. Halloran PF. Drug therapy: Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-2729.
7. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271-280.
8. van Gelder T, ter Meulen CG, Hene R, Weimar W, Hoitsma A. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003; 75: 788-791.
9. Warino L, Libecco J. Cutaneous effects of sirolimus in renal transplant recipients. J Drugs Dermatol 2006; 5: 273-274.
10. Mahe E, Morelon E, Lechaton S et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 2005; 79: 476-482.
11. Lo Muzio L, della Valle A, Mignogna MD et al. The treatment of oral aphthous ulceration or erosive lichen planus with topical clobetasol propionate in three preparations: A clinical and pilot study on 54 patients. J Oral Pathol Med 2001; 30: 611-617.
12. Gonzalez-Moles MA, Morales P, Rodriguez-Archilla A, Isabel IR, Gonzalez-Moles S. Treatment of severe chronic oral erosive lesions with clobetasol propionate in aqueous solution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 93: 264-270.
13. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605-612.
14. Meier-Kriesche HU, Li S, Gruessner RW et al. Immunosuppression: Evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6(5 Pt 2): 1111-1131.
15. Immunosuppression. 2004 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1994-2003. Ann Arbor, MI, HHS/HRSA/OSP/DOT and UNOS, 2004.
16. Kreis H, Oberbauer R, Campistol JM et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15: 809-817.
17. Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: A phase II trial. Transplantation 1999; 68: 1526-1532.
18. Shapiro AM, Lakey JR, Ryan EA et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230-238.
19. Scully C. Aphthous ulceration. N Engl J Med 2006; 355: 165-172.
20. Jurge S, Kuffer R, Scully C, Porter SR. Mucosal disease series. Number VI. Recurrent aphthous stomatitis. Oral Dis 2006; 12: 1-21.